- Home
- Blog
- News
- Basics
- Sources
- Agencies, Regulatory & Organisations
- CERSI Excipients Browser
- Excipient Report
- Excipient DMF List
- EXCiPACT Certified Companies
- Excipient Documentation
- Excipient EINECS Numbers
- Excipient E-Numbers
- FDA Inactive Ingredient List
- FDA GRAS Substances (SCOGS) Database
- IPEC Americas
- USP - U.S. Pharmacopeia
- Definitions
- Whitepapers / Publications
- Supplier
- Services
- Media
- Events
- 1st pharmaexcipients Poster Award
- Event Calendar
- Events featured by pharma-excipients
- 4th Annual Formulation & Drug Delivery Congress
- DDF Summit
- ExcipientFest Americas
- ExcipientFest Asia
- Global CompliancePanel
- International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems
- Formulation & Drug Delivery USA Congress
- Laboratory Medicine 2018
- Making Pharmaceuticals Europe
- Making Pharmaceuticals Exhibition
- Pharma Integrates
- PharmaExcipients China @CPhI China
- TTC Technology Training Center
- Jobs
- Online Sourcing
- Contact
07. February 2017
Abstract Enteric-coated fixed-dose combinations of ezetimibe and lovastatin were prepared by fluid bed coating aiming to avoid the acidic conversion of lovastatin to its hydroxyacid derivative. In a two-step process, sucrose beads were layered with a glass solution of ezetimibe, lovastatin and Soluplus®, top-coated with an enteric layer. The impact of different bead size, enteric polymers (Eudragit L100® and Eudragit L100-55®) and coating time was investigated. Samples were evaluated by...
18. February 2016
Purpose Aiming to improve the dissolution rate of ezetimibe (EZE) and lovastatin (LOV) in a fixed dose combination (FDC), co-amorphous systems and ternary solid dispersions were prepared by quench cooling and spray drying, respectively. Methods Formulations were characterized through X-ray diffraction, modulated differential scanning calorimetry, infrared spectroscopy, scanning electron microscopy and laser diffraction, and evaluated by ‘in vitro’ dissolution. Stability studies were...